Tabone M, Ercole E, Zaffino C, Sallio Bruno F, Pera A, Bonino F
Gastroenterology Division, Mauriziano Hospital, Turin, Italy.
Ital J Gastroenterol Hepatol. 1998 Dec;30(6):611-3.
To investigate the effects and tolerance of amantadine in chronic hepatitis C patients.
Forty consecutive patients, with biopsy proven chronic active hepatitis, were treated with amantadine 200 mg daily in the morning for two months. Nineteen patients were previous non responders to alpha-interferon, nine patients experienced hepatitis relapse after interferon treatment, and twelve patients had never been treated with antiviral drugs. Complete blood count, liver and renal function tests were performed two months before, at baseline, end of therapy and two months after its completion.
None of the patients experienced significant side effects. Twenty-four patients (60%) showed a reduction of serum aminotransferase levels (twelve patients > 30% and twelve patients < 30% of their basal levels). The analysis of variance showed a significant reduction in aminotransferase levels at the end of treatment (F = 11, p < 0.0001). In four patients, aminotransferases returned to normal, but none of them cleared HCV-RNA. After the end of treatment, serum ALT returned to baseline values in all patients.
Amantadine is well tolerated in chronic hepatitis C patients. The time-relation between therapy and reduction of serum aminotransferase levels in 60% of patients suggests a potential anti-inflammatory activity of the drug without an effect on viraemia.
研究金刚烷胺对慢性丙型肝炎患者的疗效及耐受性。
连续40例经活检证实为慢性活动性肝炎的患者，每天早晨服用200毫克金刚烷胺，疗程两个月。其中19例患者既往对α干扰素治疗无反应，9例患者在干扰素治疗后肝炎复发，12例患者从未接受过抗病毒药物治疗。在治疗前两个月、基线、治疗结束时及结束后两个月进行全血细胞计数、肝肾功能检查。
所有患者均未出现明显副作用。24例患者（60%）血清转氨酶水平降低（12例患者降低幅度>其基础水平的30%，12例患者降低幅度<30%）。方差分析显示治疗结束时转氨酶水平显著降低（F = 11，p < 0.0001）。4例患者转氨酶恢复正常，但均未清除HCV-RNA。治疗结束后，所有患者血清ALT均恢复至基线值。
慢性丙型肝炎患者对金刚烷胺耐受性良好。60%的患者治疗与血清转氨酶水平降低之间的时间关系提示该药物具有潜在的抗炎活性，但对病毒血症无影响。
